AHA 2023 | MINT: Liberal vs Restrictive Transfusion in Patients with Acute Coronary Syndrome

The aim of this study was to assess hard end points such as death or MI in patients with acute coronary syndrome (ACS) presenting hemoglobin levels lower than 10 mg/dl. It was a randomized multicenter double blind trial including 3506 participants. The study looked at different transfusion strategies, comparing restrictive strategy with 7-8 g/dl hemoglobin<a href="https://solaci.org/en/2023/11/16/aha-2023-mint-liberal-vs-restrictive-transfusion-in-patients-with-acute-coronary-syndrome/" title="Read more" >...</a>

ESC 2023 | FIRE-Trial: Physiology Guided Complete Revascularization Benefits Elderly Patients with Myocardial Infarction

Patients over 75 with acute coronary syndrome (ACS) are often badly represented in most significant studies.  In this context, the FIRE study looked to determine whether physiology guided complete revascularization is superior to culprit-only revascularization in elderly patients with multivessel disease suffering acute MI.  The study included SCA patients over 75, hospitalized for both STEMI<a href="https://solaci.org/en/2023/08/29/esc-2023-fire-trial-physiology-guided-complete-revascularization-benefits-elderly-patients-with-myocardial-infarction/" title="Read more" >...</a>

MACT Study: Monotherapy with P2Y12 Inhibitor Associated with Colchicine after Acute Coronary Syndrome

Dual antiplatelet therapy (DAPT) is the current standard for preventing thrombotic events in high-risk patients with coronary artery disease, as well as in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). However, this approach increases the risk of bleeding. To reduce this risk, there have been studies that discontinued the use of<a href="https://solaci.org/en/2023/08/29/mact-study-monotherapy-with-p2y12-inhibitor-associated-with-colchicine-after-acute-coronary-syndrome/" title="Read more" >...</a>

Síndrome de Tokotsubo ¿El género tiene influencia en su pronóstico?

Abbreviated Therapy in Patients with Acute Coronary Syndrome: How Safe Is Conservative DAPT Treatment?

Abbreviated dual antiplatelet therapy in patients at high risk for bleeding and acute myocardial infarction. Patients with acute coronary syndrome (ACS) who undergo stent placement (percutaneous coronary intervention, PCI) conventionally require at least 12 months of dual antiplatelet therapy (DAPT) to reduce ischemic events. Patients with ACS who are also at high risk for bleeding<a href="https://solaci.org/en/2023/06/01/abbreviated-therapy-in-patients-with-acute-coronary-syndrome-how-safe-is-conservative-dapt-treatment/" title="Read more" >...</a>

Plaque Erosion with No Stenting in Acute Coronary Syndrome: Are There Event Predictors to Avoid This Strategy?

 Event predictors in patients with plaque erosion and no stenting. A third of all acute coronary syndrome (ACS) cases are caused by plaque erosion. In the initial EROSION study, it was shown that patients with plaque erosion (as evidenced by OCT, with stenosis <70%, TIMI III flow, and asymptomatic) were stabilized without stent implantation (no<a href="https://solaci.org/en/2023/02/13/plaque-erosion-with-no-stenting-in-acute-coronary-syndrome-are-there-event-predictors-to-avoid-this-strategy/" title="Read more" >...</a>

El ticagrelor muestra beneficios en la función microvascular coronaria luego de un IAMSEST

Prophylactic Rivaroxaban Therapy for Left Ventricular Thrombus after ST-Segment Elevation Acute Coronary Syndrome

The incidence of left ventricular thrombosis (LVT) after anterior ST-segment elevation myocardial infarction (STEMI) ranges from 4% to 26%. This is associated with bad long-term evolution. In the past, triple-scheme therapy (vitamin K antagonist plus dual antiplatelet therapy) was recommended to prevent LVT, despite the lack of high-quality scientific evidence and an increase in the<a href="https://solaci.org/en/2022/05/05/prophylactic-rivaroxaban-therapy-for-left-ventricular-thrombus-after-st-segment-elevation-acute-coronary-syndrome/" title="Read more" >...</a>

Survey to Evaluate Myocardial Infarction Reperfusion in LatAm

The Latin American Society of Interventional Cardiology together with the Interamerican Society of Cardiology (SIAC) and the Stent-Save a Life! Initiative have developed a short survey (which can be answered in less than 5 minutes) to learn how ST-segment elevation acute coronary syndromes are treated in Latin America. The final objective of this survey is<a href="https://solaci.org/en/2022/04/06/survey-to-evaluate-myocardial-infarction-reperfusion-in-latam/" title="Read more" >...</a>

El uso del ultrasonido intravascular en la angioplastia de tronco no protegido se asocia con mejores resultados en comparación con la angioplastia guiada solo por angiografía.

IVUS in Acute Coronary Syndrome: A New Requirement?

The use of intravascular ultrasound (IVUS) has seen exponential growth across registries over the years, combined with mounting and increasingly robust evidence. The fact that it will enable us to characterize plaque morphology and extension prior the intervention, and even assess stent expansion post intervention, has turned it into a pillar of our efforts to<a href="https://solaci.org/en/2022/03/07/ivus-in-acute-coronary-syndrome-a-new-requirement/" title="Read more" >...</a>

AHA 2021 | RAPID CABG: seguridad de ir al quirófano precozmente en un síndrome coronario agudo

AHA 2021 | RAPID CABG: Safety of Early Surgical Intervention in Acute Coronary Syndrome

Suspending ticagrelor a couple of days before surgery was non-inferior to waiting 5-6 days in terms of bleeding in patients with acute coronary syndrome (ACS) requiring myocardial revascularization surgery. Patients who waited longer had more ischemic events and longer hospitalizations. Current American guidelines recommend waiting at least 5 days before operating on patients with ACS who<a href="https://solaci.org/en/2021/11/23/aha-2021-rapid-cabg-safety-of-early-surgical-intervention-in-acute-coronary-syndrome/" title="Read more" >...</a>

ESC 2021 | Injuria aguda y crónica por COVID-19 y su impacto en la mortalidad

ESC 2021 | Acute and Chronic Myocardial Injury in COVID-19 Patients and Impact in Mortality

In patients hospitalized for COVID-19, both acute and chronic myocardial injury impact survival at 6 months. In addition, the risk does not disappear after the acute phase of the disease, instead it persists in the following months among those who survive.  This study was presented at the scientific sessions of ESC 2021 and was simultaneously<a href="https://solaci.org/en/2021/09/06/esc-2021-acute-and-chronic-myocardial-injury-in-covid-19-patients-and-impact-in-mortality/" title="Read more" >...</a>